Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Current Deferred Revenue for 6 consecutive years, with $6.7 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 93.88% to $6.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Dec 2025, down 93.88% year-over-year, with the annual reading at $6.7 million for FY2025, 93.88% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $6.7 million at Beam Therapeutics, down from $110.3 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $338.2 million in Q4 2022, with the low at $6.7 million in Q4 2025.
  • Average Current Deferred Revenue over 5 years is $124.6 million, with a median of $110.3 million recorded in 2025.
  • The sharpest move saw Current Deferred Revenue skyrocketed 1249900.0% in 2021, then tumbled 93.88% in 2025.
  • Over 5 years, Current Deferred Revenue stood at $300.0 million in 2021, then increased by 12.72% to $338.2 million in 2022, then crashed by 47.19% to $178.6 million in 2023, then tumbled by 39.05% to $108.9 million in 2024, then crashed by 93.88% to $6.7 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $6.7 million, $110.3 million, and $105.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.